Accéder au contenu
MilliporeSigma

Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic β-catenin degradation.

Science signaling (2021-01-14)
Jingwen Yang, Megumi Kitami, Haichun Pan, Masako Toda Nakamura, Honghao Zhang, Fei Liu, Lingxin Zhu, Yoshihiro Komatsu, Yuji Mishina
RÉSUMÉ

Cranial neural crest cells (CNCCs) are a population of multipotent stem cells that give rise to craniofacial bone and cartilage during development. Bone morphogenetic protein (BMP) signaling and autophagy have been individually implicated in stem cell homeostasis. Mutations that cause constitutive activation of the BMP type I receptor ACVR1 cause the congenital disorder fibrodysplasia ossificans progressiva (FOP), which is characterized by ectopic cartilage and bone in connective tissues in the trunk and sometimes includes ectopic craniofacial bones. Here, we showed that enhanced BMP signaling through the constitutively activated ACVR1 (ca-ACVR1) in CNCCs in mice induced ectopic cartilage formation in the craniofacial region through an autophagy-dependent mechanism. Enhanced BMP signaling suppressed autophagy by activating mTORC1, thus blocking the autophagic degradation of β-catenin, which, in turn, caused CNCCs to adopt a chondrogenic identity. Transient blockade of mTORC1, reactivation of autophagy, or suppression of Wnt-β-catenin signaling reduced ectopic cartilages in ca-Acvr1 mutants. Our results suggest that BMP signaling and autophagy coordinately regulate β-catenin activity to direct the fate of CNCCs during craniofacial development. These findings may also explain why some patients with FOP develop ectopic bones through endochondral ossification in craniofacial regions.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Anti-digoxigénine-AP, fragments Fab, from sheep
Roche
Kit de détection in situ de la mort cellulaire, fluorescéine, sufficient for ≤50 tests, suitable for detection
Roche
cOmplete ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail, Tablets supplied in foil blister packs.
Sigma-Aldrich
MG-132, en solution prête à l′emploi, ≥90% (HPLC)
Sigma-Aldrich
Guanidine hydrochloride solution, 6M
Sigma-Aldrich
Chloroquine diphosphate salt, powder or crystals, 98.5-101.0% (EP)
Sigma-Aldrich
XAV939, ≥98% (HPLC)
Sigma-Aldrich
Ribonucléase A from bovine pancreas, Type II-A, ≥60% (SDS-PAGE), >= 60 Kunitz units/mg protein